Picture of Amplia Therapeutics logo

ATX — Amplia Therapeutics News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Australia's Amplia Therapeutics rises on approval for cancer treatment study

** Shares of drug developer Amplia Therapeutics  ATX.AX 
rise as much as 4.2% to A$0.125 
    ** Co receives https://www.asx.com.au/asxpdf/20220513/pdf/458yyhyhp2m4ns.pdf
 ethics clearance to conduct the Phase 2 clinical trial of its
Focal Adhesion Kinase inhibitor in first-line patients with
advanced pancreatic cancer 
    ** More than 350,000 shares change hands, compared with the
30-day average of about 165,000 shares 
    ** Stock down ~27.3% YTD, as of last close

 (Reporting by Upasana Singh in Bengaluru)
 ((Upasana.Singh@thomsonreuters.com))

Recent news on Amplia Therapeutics

See all news